144. Lennox-Gastaut syndrome Clinical trials / Disease details


Clinical trials : 101 Drugs : 68 - (DrugBank : 12) / Drug target genes : 49 - Drug target pathways : 60

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02175173
(ClinicalTrials.gov)
June 13, 201310/6/2014Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut SyndromeLennox-Gastaut SyndromeDrug: RufinamideEisai Co., Ltd.NULLRecruitingN/AN/AAll728Japan
2JPRN-JapicCTI-132169
29/5/201321/06/2013Post-marketing surveillance of long-term administration of Inovelon tablets in patients with Lennox-Gastaut syndromePost-marketing surveillance of long-term administration of Inovelon tablets in patients with Lennox-Gastaut syndrome Lennox-Gastaut syndromeIntervention name : Inovelon
INN of the intervention : Rufinamide
Dosage And administration of the intervention : Oral
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Eisai Co., Ltd.NULLrecruitingBOTH300NAJapan
3EUCTR2010-023505-36-IT
(EUCTR)
29/09/201105/01/2012A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut SyndromeA Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut Syndrome - E2080-G000-303 Lennox Gastaut Syndrome
MedDRA version: 14.1;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Inovelon
Other descriptive name: Rufinamide oral suspension
INN or Proposed INN: lamotrigine
Other descriptive name: Lamictal
INN or Proposed INN: sodio valproato
INN or Proposed INN: topimarato
Other descriptive name: topimarate
EISAI LTD UKNULLNot RecruitingFemale: yes
Male: yes
75Greece;Italy
4EUCTR2016-004952-30-Outside-EU/EEA
(EUCTR)
13/02/2017A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome PatientsA Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients Lennox-Gastaut Syndrome (LSG);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Inovelon
Product Name: rufinamide
Product Code: E2080
INN or Proposed INN: RUFINAMIDE
Eisai Co, Ltd.NULLNAFemale: yes
Male: yes
58Phase 3Japan
5EUCTR2016-004953-34-Outside-EU/EEA
(EUCTR)
23/02/2017A Long Term Extension Study of E2080 in Patients with Lennox-GastautSyndromeA Long Term Extension Study of E2080 in Patients with Lennox-GastautSyndrome Lennox-Gastaut Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Inovelon
Product Name: rufinamide
Product Code: E2080
INN or Proposed INN: RUFINAMIDE
Eisai Co, Ltd.NULLNAFemale: yes
Male: yes
54Phase 3Japan